SCHEDULE: Manchester Entities Adjust EuPhoria Pharmaceuticals Stake

Several Manchester entities and individuals have updated their beneficial ownership filings for EUPRAXIA PHARMACEUTICALS INC. common shares, with aggregate holdings now reported.

Summary

• This filing is an amendment to Schedule 13G, indicating a change in beneficial ownership of EUPRAXIA PHARMACEUTICALS INC. common shares.
• The reporting persons include Manchester Management Company, LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., James E. Besser, and Morgan C. Frank.
• The filing details the number of shares beneficially owned, voting power, and dispositive power for each reporting person as of June 30, 2026.
• Aggregate beneficial ownership for James E. Besser is 2,772,341 shares (4.5% of the class).
• Aggregate beneficial ownership for Manchester Management Company, LLC and Manchester Management PR, LLC is 2,634,048 shares each (4.3% of the class).
• Aggregate beneficial ownership for Manchester Explorer, L.P. is 2,511,121 shares (4.1% of the class).
• Aggregate beneficial ownership for Morgan C. Frank is 2,664,780 shares (4.3% of the class).
• The filing clarifies that securities not held with sole voting or dispositive power are owned by advisory clients of Manchester Management PR, LLC, none of whom are deemed to beneficially own more than 5%.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership thresholds rather than a reflection of company performance or strategic shifts.

Positives

• The filing provides transparency regarding significant beneficial ownership of EUPRAXIA PHARMACEUTICALS INC. common shares.
• The reporting persons have updated their filings, ensuring compliance with regulatory requirements.

Negatives

• The filing does not contain financial performance data or strategic updates, limiting insights into the company's operational health.
• The nature of the reporting entities (investment management, L.P.) suggests a focus on investment rather than operational control.

Risks

• Potential for increased shareholder activism or influence due to the significant aggregate ownership by the Manchester entities.
• Concentration of ownership could lead to decisions that prioritize the interests of these large shareholders over other stakeholders.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it pertains to beneficial ownership.

Management Comments

• Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• To the extent that 'ownership of 5 percent or less of a class' was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers who acquire significant stakes in public companies. This filing indicates a notable investment position in EUPRAXIA PHARMACEUTICALS INC. by the Manchester entities.

Stakeholder Impact

• Shareholders: May be influenced by the significant ownership stake and potential for coordinated action by the reporting persons.
• Management: May need to consider the interests of these large shareholders in strategic decision-making.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership levels and file amendments as required by SEC regulations.
• Further filings may be required if ownership levels change significantly.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, EUPRAXIA PHARMACEUTICALS INC., Manchester Management, Investment Management, Common Shares, SEC Filing